$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta

$prta Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000155905317000013 Filed on May 09, 2017

Income Statement

Concept	2017 Q2	2017 Q1	2016 Q1
Revenue	$26.81M	$259.0K	$265.0K
YoY Change	7951.65%	-2.26%	-55.31%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$10.91M	$10.83M	$7.180M
YoY Change	34.19%	50.84%	42.18%
% of Gross Profit
Research & Development	$34.03M	$25.70M	$20.49M
YoY Change	5.17%	25.4%	93.82%
% of Gross Profit
Depreciation & Amortization	$800.0K	$759.0K	$251.0K
YoY Change	100.0%	202.39%	30.05%
% of Gross Profit
Operating Expenses	$44.94M	$36.53M	$27.68M
YoY Change	10.99%	32.0%	77.15%
Operating Profit	-$18.13M	-$36.27M	-$27.41M
YoY Change	-54.85%	32.33%	82.38%
Interest Expense	$20.00K	-$360.0K	$280.0K
YoY Change	-300.0%	-228.57%	833.33%
% of Operating Profit
Other Income/Expense, Net	-$856.0K	-$774.0K	$70.00K
YoY Change	791.67%	-1205.71%	-24.73%
Pretax Income	-$18.99M	-$37.05M	-$27.34M
YoY Change	-52.83%	35.5%	83.05%
Income Tax	-$1.287M	-$1.661M	$181.0K
% Of Pretax Income
Net Earnings	-$17.70M	-$35.38M	-$27.52M
YoY Change	-56.23%	28.57%	81.04%
Net Earnings / Revenue	-66.02%	-13661.78%	-10385.28%
Basic Earnings Per Share	-$0.46	-$0.99	-$0.81
Diluted Earnings Per Share	-$0.46	-$0.99	-$0.81
COMMON SHARES
Basic Shares Outstanding	38.02M shares	35.03M shares	34.34M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q2	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$471.7M	$506.6M	$474.3M
YoY Change	6.5%	6.81%	69.45%
Cash & Equivalents	$471.7M	$506.6M	$474.3M
Short-Term Investments
Other Short-Term Assets	$9.800M	$7.400M	$6.800M
YoY Change	34.25%	8.82%	112.5%
Inventory
Prepaid Expenses
Receivables	$30.24M	$271.0K	$1.003M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$511.7M	$514.2M	$482.1M
YoY Change	13.56%	6.66%	69.5%
LONG-TERM ASSETS
Property, Plant & Equipment	$55.84M	$56.08M	$3.924M
YoY Change	33.43%	1329.26%	32.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.625M	$2.430M	$1.998M
YoY Change	-31.23%	21.62%	1607.69%
Total Long-Term Assets	$67.28M	$67.75M	$9.216M
YoY Change	29.47%	635.09%	78.4%
TOTAL ASSETS
Total Short-Term Assets	$511.7M	$514.2M	$482.1M
Total Long-Term Assets	$67.28M	$67.75M	$9.216M
Total Assets	$579.0M	$582.0M	$491.3M
YoY Change	15.21%	18.45%	69.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.55M	$6.254M	$7.897M
YoY Change	8.22%	-20.81%	296.83%
Accrued Expenses	$25.00M	$25.50M	$13.10M
YoY Change	26.9%	94.66%	104.69%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$39.60M	$33.68M	$23.23M
YoY Change	18.36%	44.96%	143.44%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$52.40M	$52.00M	$126.0K
YoY Change	41487.3%	41169.84%	0.0%
Total Long-Term Liabilities	$52.43M	$52.02M	$2.294M
YoY Change	37.09%	2167.74%	-12.28%
TOTAL LIABILITIES
Total Short-Term Liabilities	$39.60M	$33.68M	$23.23M
Total Long-Term Liabilities	$52.43M	$52.02M	$2.294M
Total Liabilities	$92.02M	$85.70M	$25.53M
YoY Change	28.35%	235.72%	109.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$342.2M	-$324.5M	-$156.6M
YoY Change	73.64%	107.18%	145.9%
Common Stock	$382.0K	$380.0K	$343.0K
YoY Change	11.37%	10.79%	24.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$487.0M	$496.2M	$465.8M
YoY Change
Total Liabilities & Shareholders Equity	$579.0M	$582.0M	$491.3M
YoY Change	15.21%	18.45%	69.66%

Cashflow Statement

Concept	2017 Q2	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	-$17.70M	-$35.38M	-$27.52M
YoY Change	-56.23%	28.57%	81.04%
Depreciation, Depletion And Amortization	$800.0K	$759.0K	$251.0K
YoY Change	100.0%	202.39%	30.05%
Cash From Operating Activities	-$36.08M	-$37.84M	-$25.06M
YoY Change	31.06%	51.02%	70.22%
INVESTING ACTIVITIES
Capital Expenditures	-$210.0K	-$2.500M	-$240.0K
YoY Change	-70.0%	941.67%	700.0%
Acquisitions
YoY Change
Other Investing Activities	$10.00K	$100.0K
YoY Change	-100.25%
Cash From Investing Activities	-$210.0K	-$2.399M	-$238.0K
YoY Change	-95.59%	907.98%	750.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$150.4M	$128.8M
YoY Change		16.8%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.460M	$159.9M	$129.0M
YoY Change	48.98%	23.97%	12469.3%
NET CHANGE
Cash From Operating Activities	-36.08M	-$37.84M	-$25.06M
Cash From Investing Activities	-210.0K	-$2.399M	-$238.0K
Cash From Financing Activities	1.460M	$159.9M	$129.0M
Net Change In Cash	-34.83M	$119.6M	$103.7M
YoY Change	11.24%	15.4%	-855.47%
FREE CASH FLOW
Cash From Operating Activities	-$36.08M	-$37.84M	-$25.06M
Capital Expenditures	-$210.0K	-$2.500M	-$240.0K
Free Cash Flow	-$35.87M	-$35.34M	-$24.82M
YoY Change	33.69%	42.41%	68.94%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	Prothena Corp plc
CY2017Q1	dei	Trading Symbol TradingSymbol	PRTA
CY2016Q1	prta	Accrued Offering Costs AccruedOfferingCosts	8000	USD
CY2017Q1	prta	Accrued Offering Costs AccruedOfferingCosts	107000	USD
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001559053
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	38020181	shares
CY2016Q4	prta	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	19073000	USD
CY2017Q1	prta	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	21710000	USD
CY2016Q1	prta	Buildto Suit Leases Increase Decreaseto Obligation BuildtoSuitLeasesIncreaseDecreasetoObligation	0	USD
CY2017Q1	prta	Buildto Suit Leases Increase Decreaseto Obligation BuildtoSuitLeasesIncreaseDecreasetoObligation	501000	USD
CY2016Q4	prta	Buildto Suit Property Gross BuildtoSuitPropertyGross	51359000	USD
CY2017Q1	prta	Buildto Suit Property Gross BuildtoSuitPropertyGross	51760000	USD
CY2016Q4	prta	Buildtosuitleaseobligationnoncurrent Buildtosuitleaseobligationnoncurrent	51320000	USD
CY2017Q1	prta	Buildtosuitleaseobligationnoncurrent Buildtosuitleaseobligationnoncurrent	51700000	USD
CY2017Q1	prta	Buildtosuitleaseobligationnoncurrent Buildtosuitleaseobligationnoncurrent	51735000	USD
CY2017Q1	prta	Builtto Suit Leases At Cost BuilttoSuitLeasesAtCost	51800000	USD
CY2015Q4	prta	Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents CashCashEquivalentsRestrictedCashandRestrictedCashEquivalents	370586000	USD
CY2016Q1	prta	Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents CashCashEquivalentsRestrictedCashandRestrictedCashEquivalents	474252000	USD
CY2016Q4	prta	Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents CashCashEquivalentsRestrictedCashandRestrictedCashEquivalents	390979000	USD
CY2017Q1	prta	Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents CashCashEquivalentsRestrictedCashandRestrictedCashEquivalents	510606000	USD
CY2016Q1	prta	Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	103666000	USD
CY2017Q1	prta	Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	119627000	USD
CY2016Q1	prta	Collaboration Revenue CollaborationRevenue	265000	USD
CY2017Q1	prta	Collaboration Revenue CollaborationRevenue	259000	USD
CY2016Q4	prta	Deferred Shares Par Value DeferredSharesParValue	22
CY2017Q1	prta	Deferred Shares Par Value DeferredSharesParValue	22
CY2017Q1	prta	Deferred Shares Par Value DeferredSharesParValue	22
CY2016Q4	prta	Deferred Shares Share Issued DeferredSharesShareIssued	0	shares
CY2017Q1	prta	Deferred Shares Share Issued DeferredSharesShareIssued	0	shares
CY2016Q4	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0	shares
CY2017Q1	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0	shares
CY2017Q1	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0.0	shares
CY2016Q4	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2017Q1	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2017Q1	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2016Q4	prta	Deferred Shares Value DeferredSharesValue	0	USD
CY2017Q1	prta	Deferred Shares Value DeferredSharesValue	0	USD
CY2016Q1	prta	Interest Expenseunderbuildtosuittransaction InterestExpenseunderbuildtosuittransaction	0	USD
CY2017Q1	prta	Interest Expenseunderbuildtosuittransaction InterestExpenseunderbuildtosuittransaction	916000	USD
CY2017Q1	prta	Numberof Votes NumberofVotes	1	vote
CY2017Q1	prta	Purchaseand Contractual Obligation Duein Third Year PurchaseandContractualObligationDueinThirdYear	189000	USD
CY2017Q1	prta	Purchaseand Contractual Obligation Due After Fifth Year PurchaseandContractualObligationDueAfterFifthYear	860000	USD
CY2017Q1	prta	Purchaseand Contractual Obligation Due Next Fiscal Year PurchaseandContractualObligationDueNextFiscalYear	20839000	USD
CY2017Q1	prta	Purchaseand Contractual Obligation Duein Fifth Year PurchaseandContractualObligationDueinFifthYear	100000	USD
CY2017Q1	prta	Purchaseand Contractual Obligation Duein Fourth Year PurchaseandContractualObligationDueinFourthYear	132000	USD
CY2017Q1	prta	Purchaseand Contractual Obligation Duein Second Year PurchaseandContractualObligationDueinSecondYear	242000	USD
CY2017Q1	prta	Purchaseand Contractual Obligation Total PurchaseandContractualObligationTotal	22362000	USD
CY2016Q1	prta	Receivable Stock Option Exercises ReceivableStockOptionExercises	0	USD
CY2017Q1	prta	Receivable Stock Option Exercises ReceivableStockOptionExercises	311000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13069000	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6254000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	178000	USD
CY2017Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	271000	USD
CY2016Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	378000	USD
CY2017Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	385000	USD
CY2016Q4	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	98000	USD
CY2017Q1	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	0	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	435000	USD
CY2017Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	411000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7668000	USD
CY2017Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5589000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	654266000	USD
CY2017Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	820365000	USD
CY2016Q4	us-gaap	Assets Assets	459976000	USD
CY2017Q1	us-gaap	Assets Assets	581950000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	391362000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	514204000	USD
CY2016Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	68614000	USD
CY2017Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	67746000	USD
CY2016Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	363000	USD
CY2017Q1	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	531000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	386923000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	506550000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34752116	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37957649	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37957649	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34752116	shares
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	2080000	USD
CY2017Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	287000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	5913000	USD
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37957649	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37957649	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	348000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	380000	USD
CY2016Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-445000	USD
CY2017Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	737000	USD
CY2016Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	363000	USD
CY2017Q1	us-gaap	Deferred Rent Credit DeferredRentCredit	49000	USD
CY2017Q1	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	5176000	USD
CY2016Q1	us-gaap	Depreciation Depreciation	300000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	800000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	251000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	759000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.81
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.99
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6629000	USD
CY2017Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3835000	USD
CY2016Q1	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	USD
CY2017Q1	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	2096000	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7182000	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10832000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-27340000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-37045000	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	181000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1700000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1661000	USD
CY2016Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	383000	USD
CY2017Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	609000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2831000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	494000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	93000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1181000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	5452000	USD
CY2016Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	277000	USD
CY2017Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-364000	USD
CY2016Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2769000	USD
CY2017Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	580000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	94573000	USD
CY2017Q1	us-gaap	Liabilities Liabilities	85702000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	459976000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	581950000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	41075000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	33680000	USD
CY2016Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	53498000	USD
CY2017Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	52022000	USD
CY2016Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	9629000	USD
CY2017Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	8802000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	128961000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	159868000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-238000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2399000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25057000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37842000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-27521000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-35384000	USD
CY2016Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	260000	USD
CY2017Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	88000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	70000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-774000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	27675000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	36530000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-27410000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-36271000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1861000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	166000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	221000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	221000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	221000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	221000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	811000	USD
CY2016Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	500000	USD
CY2017Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	300000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2193000	USD
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2430000	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	8555000	USD
CY2017Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5331000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-207000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-410000	USD
CY2016Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	1128000	USD
CY2017Q1	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	1036000	USD
CY2016Q1	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	238000	USD
CY2017Q1	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	2499000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4261000	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7383000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	128785000	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9948000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	150421000	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2017Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	100000	USD
CY2016Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	176000	USD
CY2017Q1	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	112000	USD
CY2017Q1	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	59000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	64120000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	61673000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	56452000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	56084000	USD
CY2017Q1	us-gaap	Purchase Obligation PurchaseObligation	20757000	USD
CY2017Q1	us-gaap	Purchase Obligation Due After Fifth Year PurchaseObligationDueAfterFifthYear	0	USD
CY2017Q1	us-gaap	Purchase Obligation Due In Fifth Year PurchaseObligationDueInFifthYear	0	USD
CY2017Q1	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	32000	USD
CY2017Q1	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	20554000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20493000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25698000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4056000	USD
CY2017Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4056000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-289211000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-324497000	USD
CY2016Q1	us-gaap	Revenues Revenues	265000	USD
CY2017Q1	us-gaap	Revenues Revenues	259000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3724000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5602000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	365403000	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	496248000	USD
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34026000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35758000	shares
CY2017Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment and Concentration of Risks</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in one segment. The Company’s chief operating decision maker (the “CODM”), its Chief Executive Officer, manages the Company’s operations on a consolidated basis for purposes of allocating resources. When evaluating the Company’s financial performance, the CODM reviews all financial information on a consolidated basis.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company places its cash equivalents with high credit quality financial institutions and by policy, limits the amount of credit exposure with any one financial institution. Deposits held with banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its credit risk exposure is up to the extent recorded on the Company's Condensed Consolidated Balance Sheet.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Receivable from Roche as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> are amounts due from Roche entities located in the U.S. and Switzerland under the License Agreement that became effective January 22, 2014. Revenue recorded in the Statements of Operations consists of reimbursement from Roche for research and development services. Credit risk exposure is up to the extent recorded on the Company's Condensed Consolidated Balance Sheet.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$55.4 million</font><font style="font-family:inherit;font-size:10pt;"> of the Company's long-lived assets were held in the U.S. and </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> were in Ireland. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$55.7 million</font><font style="font-family:inherit;font-size:10pt;"> of the Company's long-lived assets were held in the U.S. and </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> were in Ireland. </font></div><div style="line-height:120%;padding-top:15px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not own or operate facilities for the manufacture, packaging, labeling, storage, testing or distribution of preclinical or clinical supplies of any of its drug candidates, including for commercial supplies if the Company obtains regulatory approval to market any of its drug candidates. The Company instead contracts with and relies on third-parties to manufacture, package, label, store, test and distribute all pre-clinical development and clinical supplies of our drug candidates, and it plans to continue to do so for the foreseeable future, including for commercial supplies if the Company obtains regulatory approval to market any of its drug candidates. The Company also relies on third-party consultants to assist in managing these third-parties and assist with its manufacturing strategy.</font></div></div>
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, share-based compensation and research and development expenses. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Because of the uncertainties inherent in such estimates, actual results may differ materially from these estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001559053-17-000013-index-headers.html	Edgar Link	pending
0001559053-17-000013-index.html	Edgar Link	pending
0001559053-17-000013.txt	Edgar Link	pending
0001559053-17-000013-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
prta-20170331.xml	Edgar Link	completed
prta-20170331.xsd	Edgar Link	pending
prta-20170331_cal.xml	Edgar Link	unprocessable
prta-20170331_def.xml	Edgar Link	unprocessable
prta-20170331_lab.xml	Edgar Link	unprocessable
prta-20170331_pre.xml	Edgar Link	unprocessable
prta2017q110-q.htm	Edgar Link	pending
prta2017q110-qkxex321.htm	Edgar Link	pending
prta2017q110-qxex101prothe.htm	Edgar Link	pending
prta2017q110-qxex311.htm	Edgar Link	pending
prta2017q110-qxex312.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta

2017 Q2 Form 10-Q Financial Statement

#000155905317000013 Filed on May 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRTA PROTHENA CORP PUBLIC LTD CO Stock $prta

2017 Q2 Form 10-Q Financial Statement

#000155905317000013 Filed on May 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta